Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott Vuocolo

Showing results (11-20 of 36) with videos related to

Pageof 4
Sort By:
Vaccine|November 3, 2018
Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011-2016José A Suaya, Bradford D Gessner, Shirley Fung, et al.
Plos One|January 7, 2014
Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult womenJoaquin Luna, Manuel Plata, Mauricio Gonzalez, et al.
Clinical and Vaccine Immunology : CVI|June 19, 2015
Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV VaccineMari Nygård, Alfred Saah, Christian Munk, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
Development of a human papillomavirus competitive luminex immunoassay for 9 HPV typesChristine Roberts, Tina Green, Erica Hess, et al.
Vaccine|September 29, 2015
Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccineSuzanne M Garland, Tak-Hong Cheung, Shelly McNeill, et al.
Human Vaccines|February 11, 2011
The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassayDarron R Brown, Suzanne M Garland, Daron G Ferris, et al.
The Journal of Infectious Diseases|February 6, 2014
Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual menEdson Duarte Moreira, Anna R Giuliano, Joel Palefsky, et al.
International Journal of Cancer|November 15, 2007
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American womenGonzalo Perez, Eduardo Lazcano-Ponce, Mauricio Hernandez-Avila, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple MyelomaDavid S Siegel, Meletios Dimopoulos, Sundar Jagannath, et al.
Pediatrics|June 24, 2015
Immunogenicity and Safety of a 9-Valent HPV VaccinePierre Van Damme, Sven Eric Olsson, Stanley Block, et al.
Pageof 4

Showing results (11-20 of 36) with videos related to

Sort By:
Pageof 4
Vaccine|November 3, 2018
Acute otitis media, antimicrobial prescriptions, and medical expenses among children in the United States during 2011-2016José A Suaya, Bradford D Gessner, Shirley Fung, et al.
Plos One|January 7, 2014
Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil™ in adult womenJoaquin Luna, Manuel Plata, Mauricio Gonzalez, et al.
Clinical and Vaccine Immunology : CVI|June 19, 2015
Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV VaccineMari Nygård, Alfred Saah, Christian Munk, et al.
Human Vaccines & Immunotherapeutics|November 27, 2014
Development of a human papillomavirus competitive luminex immunoassay for 9 HPV typesChristine Roberts, Tina Green, Erica Hess, et al.
Vaccine|September 29, 2015
Safety and immunogenicity of a 9-valent HPV vaccine in females 12-26 years of age who previously received the quadrivalent HPV vaccineSuzanne M Garland, Tak-Hong Cheung, Shelly McNeill, et al.
Human Vaccines|February 11, 2011
The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassayDarron R Brown, Suzanne M Garland, Daron G Ferris, et al.
The Journal of Infectious Diseases|February 6, 2014
Incidence, clearance, and disease progression of genital human papillomavirus infection in heterosexual menEdson Duarte Moreira, Anna R Giuliano, Joel Palefsky, et al.
International Journal of Cancer|November 15, 2007
Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like-particle vaccine in Latin American womenGonzalo Perez, Eduardo Lazcano-Ponce, Mauricio Hernandez-Avila, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 31, 2016
VANTAGE 095: An International, Multicenter, Open-Label Study of Vorinostat (MK-0683) in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple MyelomaDavid S Siegel, Meletios Dimopoulos, Sundar Jagannath, et al.
Pediatrics|June 24, 2015
Immunogenicity and Safety of a 9-Valent HPV VaccinePierre Van Damme, Sven Eric Olsson, Stanley Block, et al.
Pageof 4